United Therapeutics UTHR
$554.73 −$4.37 (-0.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $550.23 -0.81%
Open$561.20
Prev close$559.10
Day range$551.77 – $563.12
Volume531.8K
Market cap$23.63B
P/E (TTM)20.9
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$832.50M+4.1% YoY
Operating profit$241.30M-38.0% YoY
Net profit$258.60M-23.6% YoY
Diluted EPS$5.71-20.3% YoY
Free cash flow$125.80M-64.2% YoY
Operating cash flow$306.50M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin86.3%
Operating margin39.4%
Net margin38.6%
Return on equity19.1%
Return on assets17.1%
Return on invested capital17.4%
Current ratio4.61
Liabilities / assets10.8%
Cash & investments$2.07B
Net cash (debt)$2.07B
Free cash flow / sales27.0%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $832.50M | $783.30M | $781.50M | $3.18B | $790.20M |
| Total Operating Revenue | $832.50M | $783.30M | $781.50M | $3.18B | $790.20M |
| Cost of Revenue | $99.10M | $99.50M | $133.40M | $384.40M | $103.40M |
| Gross Profit | $733.40M | $683.80M | $648.10M | $2.80B | $686.80M |
| Operating Expense | $492.10M | $353.00M | $322.30M | $1.28B | $329.30M |
| Selling and Admin Expenses | $212.90M | $206.70M | $184.10M | $731.10M | $189.80M |
| -Selling & Marketing Expense | $41.00M | $37.30M | $28.70M | $118.60M | $32.70M |
| -General & Admin Expense | $171.90M | $169.40M | $155.40M | $612.50M | $157.10M |
| Research & Development | $279.20M | $146.30M | $138.20M | $550.00M | $139.50M |
| Operating Profit | $241.30M | $330.80M | $325.80M | $1.52B | $357.50M |
| Net Non-Operating Interest Income (Expense) | $30.80M | $28.60M | $38.80M | $172.50M | $40.10M |
| Non-Operating Interest Income | $33.70M | $31.50M | $41.80M | $192.00M | $43.20M |
| Non-Operating Interest Expense | $2.90M | $2.90M | $3.00M | $19.50M | $3.10M |
| Other Income (Expense) | $100.70M | $13.30M | -$46.30M | $24.20M | $46.40M |
| Special Income (Charges) | $66.50M | $0.00 | – | -$24.70M | -$800,000.00 |
| -Less:Impairment of Capital Assets | $0.00 | $0.00 | – | $21.70M | $0.00 |
| -Less:Other Special Charges | -$66.50M | – | – | $3.00M | $800,000.00 |
| Other Non-Operating Income (Expenses) | $34.20M | $13.30M | -$46.30M | $48.90M | $47.20M |
| Pretax Profit | $372.80M | $372.70M | $318.30M | $1.71B | $444.00M |
| Tax | $114.20M | $39.70M | $43.40M | $379.20M | $79.70M |
| Net Profit | $258.60M | $333.00M | $274.90M | $1.33B | $364.30M |
| Profit from Continuing Operations | $258.60M | $333.00M | $274.90M | $1.33B | $364.30M |
| Net Income to Parent Company | $258.60M | $333.00M | $274.90M | $1.33B | $364.30M |
| Net Income to Common Stockholders | $258.60M | $333.00M | $274.90M | $1.33B | $364.30M |
| Basic EPS | $6.06 | $7.82 | $6.32 | $30.13 | $8.41 |
| Diluted EPS | $5.71 | $7.27 | $5.82 | $27.86 | $7.70 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $7.03B | $7.22B | $6.71B | $7.88B | $7.88B |
| Total Current Assets | $2.88B | $3.48B | $2.87B | $3.70B | $3.70B |
| Cash and Cash Equivalents & Short-Term Investments | $2.07B | $2.66B | $2.15B | $2.92B | $2.92B |
| -Cash and Cash Equivalents | $1.19B | $1.80B | $1.28B | $1.56B | $1.56B |
| -Short Term Investments | $879.00M | $859.10M | $874.00M | $1.36B | $1.36B |
| Receivables | $348.60M | $310.30M | $312.00M | $350.20M | $350.20M |
| -Accounts Receivable | $348.60M | $310.30M | $312.00M | $350.20M | $350.20M |
| Inventory | $201.90M | $193.80M | $178.30M | $183.10M | $183.10M |
| Other Current Assets | $261.80M | $317.30M | $228.00M | $248.90M | $248.90M |
| Total Non-Current Assets | $4.15B | $3.74B | $3.84B | $4.18B | $4.18B |
| Net PPE | $2.04B | $1.93B | $1.84B | $1.73B | $1.73B |
| -Gross PPE | $2.68B | $2.54B | $2.43B | $2.30B | $2.30B |
| -Accumulated Depreciation | -$636.30M | -$612.10M | -$589.30M | -$567.80M | -$567.80M |
| Investments and Advances | $1.47B | $1.14B | $1.32B | $1.78B | $1.78B |
| -Available for Sale Securities | $1.47B | $1.14B | $1.32B | $1.78B | $1.78B |
| Goodwill and Other Intangible Assets | $114.60M | $114.10M | $115.50M | $116.50M | $116.50M |
| Non-Current Deferred Assets | $270.20M | $311.60M | $335.40M | $357.70M | $357.70M |
| Other Non-Current Assets | $259.40M | $239.50M | $233.20M | $196.90M | $196.90M |
| Total Liabilities | $758.10M | $819.80M | $813.10M | $783.80M | $783.80M |
| Total Current Liabilities | $624.30M | $607.80M | $599.10M | $560.60M | $560.60M |
| Other Current Liabilities | $104.10M | $110.00M | $100.80M | $72.60M | $72.60M |
| Total Non-Current Liabilities | $133.80M | $212.00M | $214.00M | $223.20M | $223.20M |
| Other Non-Current Liabilities | $133.80M | $212.00M | $214.00M | $223.20M | $223.20M |
| Total Equity | $6.28B | $6.40B | $5.90B | $7.10B | $7.10B |
| Stockholders' Equity | $6.28B | $6.40B | $5.90B | $7.10B | $7.10B |
| Capital Stock | $800,000.00 | $800,000.00 | $800,000.00 | $800,000.00 | $800,000.00 |
| -Common Stock | $800,000.00 | $800,000.00 | $800,000.00 | $800,000.00 | $800,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.02B | $2.90B | $2.52B | $2.80B | $2.80B |
| Retained Earnings | $9.42B | $9.16B | $8.83B | $8.56B | $8.56B |
| Less: Treasury Stock | -$6.14B | -$5.64B | -$5.44B | -$4.26B | -$4.26B |
| Gains/Losses Not Affecting Retained Earnings | -$30.30M | -$16.20M | -$10.20M | $900,000.00 | $900,000.00 |
| -Goodwill | – | – | – | $32.30M | $32.30M |
| -Other Intangible Assets | – | – | – | $84.20M | $84.20M |
| Payables | – | – | – | $7.10M | $7.10M |
| -Accounts Payable | – | – | – | $7.10M | $7.10M |
| Current Accrued Expenses | – | – | – | $480.90M | $480.90M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $306.50M | $313.60M | $463.30M | $1.56B | $346.20M |
| Net cash flow from continuing operations | $306.50M | $313.60M | $463.30M | $1.56B | $346.20M |
| Net Income from Continuing Operations | $258.60M | $333.00M | $274.90M | $1.33B | $364.30M |
| Depreciation & Depletion & Amortization | $26.40M | $24.20M | $22.60M | $85.60M | $22.80M |
| Deferred Tax | $48.50M | $25.70M | $25.90M | $97.70M | -$3.20M |
| Other Non-Cash Items | -$11.10M | $24.80M | $32.00M | -$19.70M | -$30.20M |
| Change in Working Capital | -$37.70M | -$124.10M | $12.40M | -$106.50M | -$43.00M |
| -Change in Receivables | -$38.30M | $1.70M | $38.20M | -$70.90M | -$52.50M |
| -Change in Inventory | -$25.60M | -$17.70M | -$40.10M | -$52.60M | -$16.50M |
| -Change in Payables and Accrued Expense | $46.70M | -$4.00M | -$12.70M | $97.90M | $23.20M |
| -Change In Other Working Capital | -$20.50M | -$104.10M | $27.00M | -$80.90M | $2.80M |
| Net cash flow from investing | -$510.60M | $87.50M | $743.70M | -$551.30M | -$227.60M |
| Net Cash Flow from Continuing Investing Activities | -$510.60M | $87.50M | $743.70M | -$551.30M | -$227.60M |
| Net PPE Purchase and Sale | -$180.70M | -$108.00M | -$100.80M | -$520.50M | -$172.90M |
| Net Business Purchase and Sale | $0.00 | $0.00 | -$25.00M | -$55.00M | -$25.00M |
| Net Investment Purchase and Sale | -$345.80M | $196.20M | $875.20M | $40.10M | -$34.80M |
| Net Other Investing Changes | $15.90M | -$700,000.00 | -$5.70M | -$10.40M | $10.60M |
| Financing Cash Flow | -$410.20M | $122.40M | -$1.48B | -$1.15B | $98.40M |
| Net Cash Flow from Continuing Financing Activities | -$410.20M | $122.40M | -$1.48B | -$1.15B | $98.40M |
| Net Issuance Payments Of Debt | $0.00 | $0.00 | $0.00 | -$300.00M | $0.00 |
| Net Common Stock Issuance | -$500.80M | -$58.80M | -$1.50B | -$1.02B | -$600,000.00 |
| Proceeds from Stock Option Exercised | $92.40M | $126.30M | $73.90M | $183.10M | $99.00M |
| Net Other Financing Charges | -$1.80M | $54.90M | -$58.30M | -$16.50M | $0.00 |
| Ending Cash Balance | $1.19B | $1.80B | $1.28B | $1.56B | $1.56B |
| Net Change in Cash | -$614.30M | $523.50M | -$277.40M | -$140.10M | $217.00M |
| Beginning Cash Balance | $1.80B | $1.28B | $1.56B | $1.70B | $1.34B |
| Free Cash Flow | $125.80M | $205.60M | $362.50M | $1.04B | $167.80M |
| Gain/Loss from Continuing Operations | – | -$13.40M | $61.60M | – | – |
| Net Intangibles Purchase and Sale | – | – | – | -$5.50M | $0.00 |
No comments yet — be the first to weigh in on UTHR.
Sign in to join the discussion.